Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?

Patrick Neven, Francois Duhoux, Philippe Aftimos, Patrick Berteloot, Evandro de Azambuja, Cleo De Backer, Debbie Debaere, Françoise Derouane, Christel Fontaine, Sileny Han, Greet Huygh, Michail Ignatiadis, Eline Naert, Kevin Punie, Annelies Requilé, Christos Sotiriou, Wiebren Tjalma, Koen Traen, Yannick Van Herck, Hans Wildiers

Open source

DOI: 10.1016/j.ejca.2026.117808
Published: 2026-12
Container: European Journal of Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.117808,
  title = {Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?},
  author = {Patrick Neven and Francois Duhoux and Philippe Aftimos and Patrick Berteloot and Evandro de Azambuja and Cleo De Backer and Debbie Debaere and Françoise Derouane and Christel Fontaine and Sileny Han and Greet Huygh and Michail Ignatiadis and Eline Naert and Kevin Punie and Annelies Requilé and Christos Sotiriou and Wiebren Tjalma and Koen Traen and Yannick Van Herck and Hans Wildiers},
  year = {2026},
  journal = {European Journal of Cancer},
  doi = {10.1016/j.ejca.2026.117808},
  url = {https://doi.org/10.1016/j.ejca.2026.117808}
}

RIS

TY  - JOUR
TI  - Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?
AU  - Patrick Neven
AU  - Francois Duhoux
AU  - Philippe Aftimos
AU  - Patrick Berteloot
AU  - Evandro de Azambuja
AU  - Cleo De Backer
AU  - Debbie Debaere
AU  - Françoise Derouane
AU  - Christel Fontaine
AU  - Sileny Han
AU  - Greet Huygh
AU  - Michail Ignatiadis
AU  - Eline Naert
AU  - Kevin Punie
AU  - Annelies Requilé
AU  - Christos Sotiriou
AU  - Wiebren Tjalma
AU  - Koen Traen
AU  - Yannick Van Herck
AU  - Hans Wildiers
PY  - 2026
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2026.117808
UR  - https://doi.org/10.1016/j.ejca.2026.117808
ER  -

APA

Neven, P., Duhoux, F., Aftimos, P., Berteloot, P., Azambuja, E. D., Backer, C. D., Debaere, D., Derouane, F., Fontaine, C., Han, S., Huygh, G., Ignatiadis, M., Naert, E., Punie, K., Requilé, A., Sotiriou, C., Tjalma, W., Traen, K., Herck, Y. V., & Wildiers, H. (2026). Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117808

Source records

crossref · retrieved 2026-11-05T05:16:11.268Z